Mechanistically, through inhibiting cancer ferroptosis in a PI3K‐Akt signaling‐dependent manner, ANO1 enhances tumor progression and facilitates cancer‐associated fibroblast recruitment by promoting TGF‐β release, thus crippling CD8+ T cell‐mediated anti‐tumor immunity and generating resistance to immunotherapy. Here, ANO1 is linked to neoplasm.